MARLBOROUGH, Mass.,
Oct. 11, 2017 /PRNewswire/ --
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage
RNAi company developing innovative therapeutics that address
significant unmet medical needs, announced today that Dr.
Karen Bulock, Vice President of
Research at RXi Pharmaceuticals, will present at 2017 Annual BIO
Investor Forum. Dr. Bulock will discuss the Company's proprietary
self-delivering RNAi (sd-rxRNA®) platform and demonstrate its broad
applicability for cell-based immunotherapies to treat cancer.
The conference will take place October
17-18, 2017, at the Westin St. Francis Hotel in San Francisco, CA.
Date: Wednesday, October 18,
2017
Time: 2:45 pm Pacific
Track: Platform for Therapeutics
Location:
Elizabethan C
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
This international investor conference draws private equity,
public investors, research analysts and industry executives from
leading global pharmaceutical and established biotechnology
companies focused on investment and business development
opportunities in the life sciences industry.
The presentation will be webcast, and the link is available
under the "Investors – Events and Presentations" section of the
Company's website, www.rxipharma.com.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
clinical-stage company developing innovative therapeutics that
address significant unmet medical needs. Building on the
pioneering discovery of RNAi, scientists at RXi have harnessed the
naturally occurring RNAi process which can be used to "silence" or
down-regulate the expression of a specific gene that may be
overexpressed in a disease condition. RXi developed a robust RNAi
therapeutic platform, including self-delivering RNA (sd-rxRNA®)
compounds, that have the ability to highly selectively block the
expression of any target in the genome, thus providing
applicability to many therapeutic areas. Our current programs
include dermatology, ophthalmology, and cell-based immunotherapy.
RXi's extensive patent portfolio provides for multiple product and
business development opportunities across a broad spectrum of
therapeutic areas, and we actively pursue research collaborations,
partnering and out-licensing opportunities with academia and
pharmaceutical companies. For additional information, visit the
Company's website, www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about: our ability to successfully develop RXI-109, Samcyprone™ and
our other product candidates (collectively "our product
candidates"); the future success of our clinical trials with our
product candidates; the timing for the commencement and completion
of clinical trials; our ability to enter into strategic
partnerships and the future success of these strategic
partnerships; and our ability to deploy our sd-rxRNA® technology
through partnerships, as well as the prospects of these
partnerships to provide positive returns. Forward-looking
statements about expectations and development plans of RXi's
product candidates and partnerships involve significant risks and
uncertainties, including the following: risks that we may not be
able to successfully develop and commercialize our product
candidates; risks that product development and clinical studies may
be delayed, not proceed as planned and/or be subject to significant
cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
View original
content:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-at-the-2017-annual-bio-investor-forum-300534570.html
SOURCE RXi Pharmaceuticals Corporation